FREMONT, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will present a company overview at the H.C.
Oral presentation of the safety and efficacy of Qtrypta TM in a long-term safety study for the acute treatment of migraine. Poster on the results of patients’ freedom from pain and most bothersome symptom when taking Qtrypta concurrently with prophylactic anti-CGRP antibodies.
Conference call scheduled for 1:30 p.m. PT today FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019 , as well as recent business
FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to initiate a Phase
FREMONT, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss results for the second quarter of 2019
Migraine Assessment of Current Therapy (or Migraine-ACT) Scores Highlight the Effectiveness of Qtrypta in Treating Migraines FREMONT, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of
FREMONT, Calif. , July 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis , senior vice president of operations at Zosano Pharma , will be presenting a keynote speech entitled, “A Novel Intracutaneous
FREMONT, Calif. , July 01, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with the management of their migraines, following
Technical Transfer of manufacturing process to CMO signals commencement of commercial readiness activities NDA planned for Q4 2019 FREMONT, Calif. , June 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has
Multiple catalysts, including Qtrypta TM NDA submission, anticipated in 2019 Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle technology Conference call scheduled for 1:30 pm PT today FREMONT, Calif.
